BRAF News

News

Vemurafenib for Pediatric Patients With Tumors Harboring BRAF V600 Mutations

08/09/2024

Though the phase 2 MATCH trial was terminated early due to poor accrual, vemurafenib did appear to be tolerable and a potential treatment option among pediatric patients with tumors harboring BRAF-V600 mutations.

Though the phase 2 MATCH trial...

08/09/2024

Oncology

News

Addition of Targeted Therapy Induction Phase to Combined Immunotherapy for Patients with BRAF-V600E/K Mutant Melanoma

06/20/2024

Allison Casey ;

According to a phase 2 study, there was no difference in PFS between a combined immunotherapy regimen and a targeted therapy induction followed by combined immunotherapy among patients with BRAF/V600E/K mutant melanoma.

According to a phase 2 study,...

06/20/2024

Oncology

News

First-Line Treatment in Left-Sided, RAS/BRAF Wild-Type Metastatic Colorectal Cancer: EGFR Inhibitors vs VEGF Inhibitors

03/26/2022

Alex Stoia ;

Pashtoon M. Kasi, MD, MS, argued for EGFR inhibitors as a superior first-line treatment vs VEGF in a debate with Cathy Eng, MD, FACP, FASCO, at the 2022 Great Debates and Updates in GI Malignancies meeting.

Pashtoon M. Kasi, MD, MS, argued...

03/26/2022

Oncology

Conference Insider

Vemurafenib Beneficial for Nonmelanoma Cancers With BRAF V600 Mutations

09/19/2020

Study data presented by Pascale Tomasini, MD, and co-investigators at the 2020 ESMO Virtual Congress show that vemurafenib has an important role in the treatment of BRAF V600-mutated nonmelanoma cancers.

Study data presented by Pascale...

09/19/2020

Oncology

News

FDA Approves Atezolizumab Combo for BRAF V600+ Melanoma

08/03/2020

The FDA has approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

The FDA has approved...

08/03/2020

Oncology

News

Meta-Analysis Supports Consideration of MSI Status in BRAF V600E-Positive CRC

01/14/2020

Meta-analysis findings suggest that MSI status should be considered as a stratification factor for better management of patients with BRAF V600E-positive CRC.

Meta-analysis findings suggest...

01/14/2020

Oncology

News

Triplet Regimen Significantly Improves OS in BRAF V600E-Mutated Metastatic CRC

10/18/2019

Encorafenib, combined with cetuximab and binimetinib resulted in significantly longer OS and a higher response rate compared with standard therapy in patients with metastatic CRC harboring the BRAF v600E mutation.

Encorafenib, combined with...

10/18/2019

Oncology

News

Combined BRAF and MEK Inhibition Offers Survival Benefit in Melanoma

08/29/2019

Combined BRAF/MEK inhibition improved survival in patients with metastatic melanoma, despite GI toxicities.

Combined BRAF/MEK inhibition...

08/29/2019

Oncology

News

Incidence of Microsatellite Instability in Metastatic CRC High, Tied to Worse Survival

06/13/2019

Results from a recent study of patients with metastatic CRC suggest that immunotherapy should be considered as first-line treatment in those with MSI-H tumors.

Results from a recent study of...

06/13/2019

Oncology

News

Baseline Prognostic Factors for Metastatic Melanoma With BRAF V600 Mutation

08/08/2018

Baseline lactate dehydrogenase level, performance status, disease burden, and gene signature are key factors for determining the survival outcomes of patients with BRAF V600 mutation–positive metastatic melanoma.

Baseline lactate dehydrogenase...

08/08/2018

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology